Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study.
Vernieri F, Brunelli N, Guerzoni S, Iannone LF, Baraldi C, Rao R, Schiano di Cola F, Ornello R, Cevoli S, Lovati C, Albanese M, Perrotta A, Cetta I, Rossi SS, Taranta V, Filippi M, Geppetti P, Sacco S, Altamura C. Vernieri F, et al. Among authors: cetta i. J Neurol. 2023 Nov;270(11):5436-5448. doi: 10.1007/s00415-023-11872-2. Epub 2023 Jul 19. J Neurol. 2023. PMID: 37468621
Stress in paediatric migraine: a trigger factor?
Colombo B, Cetta I, Messina R, Filippi M. Colombo B, et al. Among authors: cetta i. Neurol Sci. 2020 Dec;41(Suppl 2):447-449. doi: 10.1007/s10072-020-04654-5. Neurol Sci. 2020. PMID: 32845480 No abstract available.
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).
Barbanti P, Egeo G, Aurilia C, d'Onofrio F, Albanese M, Cetta I, Di Fiore P, Zucco M, Filippi M, Bono F, Altamura C, Proietti S, Bonassi S, Vernieri F; FRIEND-Study Group. Barbanti P, et al. Among authors: cetta i. J Headache Pain. 2022 Apr 9;23(1):46. doi: 10.1186/s10194-022-01396-x. J Headache Pain. 2022. PMID: 35397503 Free PMC article.
Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).
Barbanti P, Egeo G, Aurilia C, d'Onofrio F, Albanese M, Cetta I, Di Fiore P, Zucco M, Filippi M, Bono F, Altamura C, Proietti S, Bonassi S, Vernieri F; and for the FRIEND-Study Group. Barbanti P, et al. Among authors: cetta i. J Headache Pain. 2022 Apr 28;23(1):51. doi: 10.1186/s10194-022-01422-y. J Headache Pain. 2022. PMID: 35484489 Free PMC article. No abstract available.
Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).
Barbanti P, Egeo G, Aurilia C, d'Onofrio F, Albanese M, Cetta I, Di Fiore P, Zucco M, Filippi M, Bono F, Altamura C, Proietti S, Bonassi S, Vernieri F; FRIEND-Study Group. Barbanti P, et al. Among authors: cetta i. J Headache Pain. 2022 Jun 7;23(1):64. doi: 10.1186/s10194-022-01434-8. J Headache Pain. 2022. PMID: 35672670 Free PMC article. No abstract available.
16 results